🔗 Share this article The Global Health Body Sounds Alert Over Acute Shortage of Obesity Jabs Fewer than one in 10 patients who could benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it releases its first recommendations on the medications. Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging more widespread and fairer availability to GLP-1 medication. According to forecasts, over two billion are projected to be obese by 2030 unless action is taken. "Our new guidance recognises that excess weight is a chronic disease that can be addressed with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are key barriers to universal availability to the jabs that can aid individuals in losing substantial weight, says the body. Weight-Loss Drug Supply Crisis Despite the present most favorable outlook, the production of these medications would only suffice for around 100 million people – fewer than 10% of those who need them, according to the WHO. The guideline encourages countries and companies to expand access, through strategies like licensing agreements. Exclusive production rights on a key compound – the core component of a leading brand – is scheduled to end in several countries in 2026. How Weight-Loss Drugs Function These medications replicate a natural hormone to delay gastric emptying, suppress the appetite and enhance the sense of being full so users reduce food intake. Individuals commonly start to lose weight within a few weeks of beginning the regular doses. Evidence indicates users may regain a significant portion after a year of halting the treatment, because their usual hunger resume. Being above a healthy weight increases your chance for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies. Obesity concerns people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.
Fewer than one in 10 patients who could benefit from weight-loss injections such as Wegovy are able to get them, warns the World Health Organization as it releases its first recommendations on the medications. Considering in excess of 1,000,000,000 people worldwide currently living with obesity, it is urging more widespread and fairer availability to GLP-1 medication. According to forecasts, over two billion are projected to be obese by 2030 unless action is taken. "Our new guidance recognises that excess weight is a chronic disease that can be addressed with holistic and ongoing support," stated its chief Tedros Adhanom Ghebreyesus. Significant expense, limited production capacity, and supply-chain constraints are key barriers to universal availability to the jabs that can aid individuals in losing substantial weight, says the body. Weight-Loss Drug Supply Crisis Despite the present most favorable outlook, the production of these medications would only suffice for around 100 million people – fewer than 10% of those who need them, according to the WHO. The guideline encourages countries and companies to expand access, through strategies like licensing agreements. Exclusive production rights on a key compound – the core component of a leading brand – is scheduled to end in several countries in 2026. How Weight-Loss Drugs Function These medications replicate a natural hormone to delay gastric emptying, suppress the appetite and enhance the sense of being full so users reduce food intake. Individuals commonly start to lose weight within a few weeks of beginning the regular doses. Evidence indicates users may regain a significant portion after a year of halting the treatment, because their usual hunger resume. Being above a healthy weight increases your chance for developing diseases, like type 2 diabetes, cardiovascular issues, brain attack, and some malignancies. Obesity concerns people in all nations and was associated with 3.7 million fatalities worldwide in 2024, as per the health agency.